New clinical developments in drug therapy for ovarian cancer: results of the annual congress «Cancer in women» 2022

Introduction. In the Russian Federation, a trend towards an increase in diseases of the female reproductive system is recorded (38% is the proportion of patients with this pathology who have been under dispensary observation for at least 5 years). Over the years, new results from randomized, controlled clinical trials in women with cancer have been accumulating. A serious challenge for scientists is the problem of overcoming the phenomenon of «escape» of the tumor during systemic drug therapy. In this regard, the rationale for choosing the most effective treatment options is being carried out, by determining predictive and prognostic biomarkers. From March 18 to 21, 2022, the Women's Cancer Annual Congress (USA), organized by the Gynecological Oncology Society, was held, where, among others, important results of clinical trials of ovarian cancer therapy were announced.Target. Summarizing the results of clinical trials discussed on the digital platform of the Dutch educational platform for healthcare professionals in connection with their presentation at the Congress of the Oncogynecological Society on Cancer of the Female Reproductive System in March 2022.Materials and methods. The scientific study was based on the results of a search in the database of the Dutch educational platform for healthcare professionals, the PubMed / Medline database and the Google search engine. We analyzed the results published at the beginning of 2022.Results. Systematized and studied the results of new clinical developments on the drug therapy of patients with ovarian cancer, presented at the congress of the Oncogynecological Society. To date, breakthrough results of innovative clinical studies have been obtained in the world with the definition of effective approaches to the choice of individualized targeted, immuno- and chemotherapy for the treatment of patients with ovarian cancer: SOLO3, PRIME, SORAYA, iPOCC, ARTISTRY-1, etc.Discussion and conclusions. Taking into account the results of the conference, it seems clear that personalized technologies are a long-awaited and promising approach. Despite many challenges, these individualized treatment principles are slowly becoming the daily reality of oncological care for ovarian cancer patients.